Luca Pagliaro

Dr. Luca Pagliaro

Università degli Studi di Parma
+1
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2024 in Nature Reviews Disease Primers
Verified
Journal Article
Closed access
PDF file
Luca PagliaroLuca Pagliaro
Luca Pagliaro
SCSai-Juan Chen
Sai-Juan Chen
DHDaniel Herranz Herranz
Daniel Herranz Herranz
CMCristina Mecucci
Cristina Mecucci
CHChristine J. Harrison
Christine J. Harrison
RGRoti Giovanni
Roti Giovanni

7 May 2020 in Cell Chemical Biology
Verified
Journal Article
Closed access
MMMatteo Marchesini
Matteo Marchesini
AGAndrea Gherli
Andrea Gherli
AMAnna Montanaro
Anna Montanaro
LPLaura Patrizi
Laura Patrizi
CSClaudia Sorrentino
Claudia Sorrentino
RGRoti Giovanni
Roti Giovanni

29 September 2020 in Cells
Verified
Journal Article
Open access
PDF file
Luca PagliaroLuca Pagliaro
Luca Pagliaro
CSClaudia Sorrentino
Claudia Sorrentino
RGRoti Giovanni
Roti Giovanni
The Notch family comprises a group of four ligand-dependent receptors that control evolutionarily conserved developmental and homeostatic processes and transmit signals to the microenvironment. NOTCH undergoes remodeling, maturation, and trafficking in a series of post-translational events, including glycosylation, ubiquitination, and endocytosis. The regulatory modifications occurring in the endoplasmic reticulum/Golgi precede the intramembrane γ-secretase proteolysis and the transfer of active NOTCH to the nucleus. Hence, NOTCH proteins coexist in different subcellular compartments and undergo continuous relocation. Various factors, including ion concentration, enzymatic activity, and co-regulatory elements control Notch trafficking. Interfering with these regulatory mechanisms represents an innovative therapeutic way to bar oncogenic Notch signaling. In this review, we briefly summarize the role of Notch signaling in cancer and describe the protein modifications required for NOTCH to relocate across different subcellular compartments. We focus on the functional relationship between these modifications and the corresponding therapeutic options, and our findings could support the development of trafficking modulators as a potential alternative to the well-known γ-secretase inhibitors.

6 March 2018 in Leukemia
Verified
Journal Article
Open access
PDF file
EMElena Masselli
Elena Masselli
CCCecilia Carubbi
Cecilia Carubbi
BCBenedetta Cambò
Benedetta Cambò
GPGiulia Pozzi
Giulia Pozzi
GGGiuliana Gobbi
Giuliana Gobbi
MVMarco Vitale
Marco Vitale

23 May 2025 in Genes
Verified
Journal Article
Open access
PDF file
BMBarbara Moschella
Barbara Moschella
SBSabrina Busciglio
Sabrina Busciglio
EAEnrico Ambrosini
Enrico Ambrosini
SCSofia Cesarini
Sofia Cesarini
LCLuca Caramanna
Luca Caramanna
Antonio PercesepeAntonio Percesepe
Antonio Percesepe
Darier′s disease (DD) is a rare, autosomal dominant genodermatosis caused by pathogenic variants in the ATP2A2 gene, which encodes the SERCA2 protein, an endoplasmic reticulum ATPase Ca2+ transporter. These mutations impair the intracellular calcium homeostasis leading to increased protein misfolding, endoplasmic reticulum (ER) stress response, and the activation of the unfolded protein response (UPR), culminating in keratinocyte apoptosis and anomalies in interfollicular epidermal stratification. Clinically, the disease is characterized by the presence of skin lesions with hyperkeratotic papules and an increased susceptibility to inflammatory reactions, bacterial and viral infections. The histological hallmarks include acantholysis, dyskeratosis, and increased apoptotic keratinocytes, referred to as “corp ronds”. The SERCA2b isoform is expressed not only in the epidermis but it is present ubiquitously in all tissues, suggesting that its alteration may have multi-organ effects. The review aims to provide a broad overview of the pathology, from intracellular dysfunction to the clinical manifestations, elucidating the molecular effects of SERCA2 variants found in DD patients and exploring the potential cell signaling pathways that may contribute to disease progression. Beginning with an examination of the cellular alterations, our work then shifts to exploring their impact in an organ-specific context, providing insights into new potential therapeutic strategies tailored to clinical manifestations.

Verified
Journal Article
Open access
PDF file
Luca PagliaroLuca Pagliaro
Luca Pagliaro
ECElisa Cerretani
Elisa Cerretani
FVFederica Vento
Federica Vento
AMAnna Montanaro
Anna Montanaro
LTLucas Moron Dalla Tor
Lucas Moron Dalla Tor
RGRoti Giovanni
Roti Giovanni
NOTCH1 PEST domain mutations are often seen in hematopoietic malignancies, including T-cell acute lymphoblastic leukemia (T-ALL), chronic lymphocytic leukemia (CLL), splenic marginal zone lymphoma (SMZL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL). These mutations play a key role in the development and progression of lymphoproliferative tumors by increasing the Notch signaling and, consequently, promoting cell proliferation, survival, migration, and suppressing apoptosis. There is currently no specific treatment available for cancers caused by NOTCH1 PEST domain mutations. However, several NOTCH1 inhibitors are in development. Among these, inhibition of the Sarco-endoplasmic Ca2+-ATPase (SERCA) showed a greater effect in NOTCH1-mutated tumors compared to the wild-type ones. One example is CAD204520, a benzimidazole derivative active in T-ALL cells harboring NOTCH1 mutations. In this study, we preclinically assessed the effect of CAD204520 in CLL and MCL models and showed that NOTCH1 PEST domain mutations sensitize cells to the anti-leukemic activity mediated by CAD204520. Additionally, we tested the potential of CAD204520 in combination with the current first-line treatment of CLL, venetoclax, and ibrutinib. CAD204520 enhanced the synergistic effect of this treatment regimen only in samples harboring the NOTCH1 PEST domain mutations, thus supporting a role for Notch inhibition in these tumors. In summary, our work provides strong support for the development of CAD204520 as a novel therapeutic approach also in chronic lymphoproliferative disorders carrying NOTCH1 PEST domain mutations, emerging as a promising molecule for combination treatment in this aggressive subset of patients.